Price Of TB Treatment To Drop Significantly In 100 LMICs Under Deal Among Unitaid, Global Fund, Sanofi

The Guardian: Antibiotic price drop could stop millions from developing tuberculosis
“The price of a drug crucial to prevent tuberculosis is to be slashed by two-thirds in a deal that could stop millions from developing the disease. … Access to the antibiotic, rifapentine, would stop this ‘latent’ TB from becoming active. … The price drop, negotiated on a volume basis by Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the pharmaceutical company Sanofi, means the drug can be used in 100 low- and middle-income countries…” (Lamble, 10/31).

Additional coverage of the deal is available from Devex, Health24, and Science.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.